Stocks and Investing
Stocks and Investing
Thu, October 5, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Michael Okunewitch Initiated (ACRV) at Strong Buy and Held Target at $24 on, Oct 5th, 2023
Michael Okunewitch of Maxim Group, Initiated "Acrivon Therapeutics, Inc." (ACRV) at Strong Buy and Held Target at $24 on, Oct 5th, 2023.
Michael has made no other calls on ACRV in the last 4 months.
There are 2 other peers that have a rating on ACRV. Out of the 2 peers that are also analyzing ACRV, 0 agree with Michael's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Michael
- Emily Bodnar of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $20 on, Wednesday, September 6th, 2023
- Soumit Roy of "JonesTrading" Initiated at Strong Buy and Held Target at $26 on, Friday, August 18th, 2023
Contributing Sources